Note the differences in the last two ARS
STILL WAITING FOR CVS?????
This year 2021, the Company has entered into an agreement with CVS Pharmacy to participate in their Test &
Learn Program for our flagship product, Emesyl®. We initially received two purchase orders from CVS which
involved shipping Emesyl® products to two CVS distribution centers in Texas. From there, we expect the program
to place Emesyl® in 100 retail stores across the country, entering into a 24-week analysis phase. We expect to
gather weekly feedback with performance metrics via an online dashboard to develop action plans for sales
success. CVS seems to like the uniqueness of Emesyl® with it being “Homeopathic” and the “only fast acting
nasal spray” on the market. If the success criteria are met, an action plan will be developed by the CVS category
manager to expand distribution to 8000+ stores, which is typically executed in their next CVS planogram cycle.
At this moment, we will see what the Test & Learn Program will tell us.
In 2021, the Company agreed with CVS Pharmacy to participate in their Test & Learn Program for our Emesyl®
product. We fulfilled various purchase orders from CVS which involved shipping Emesyl® products to two CVS
distribution centers in Texas. We had expected to gather feedback with performance metrics via an online
dashboard to develop action plans for sales success. CVS seemed to like the uniqueness of Emesyl® with it
being “Homeopathic” and the “only fast acting nasal spray” on the market. If the success criteria are met, an
action plan will be developed by the CVS category manager to expand distribution to more of their stores, which
is typically executed in their next CVS planogram cycle. We will see what the Test & Learn Program will tell us.
Meanwhile, the Company’s Itonis Holdings, Inc. subsidiary owns and manages the entirety of the Emesyl®
nausea relief product line by full assignment of all the patent rights in Emesyl® nausea relief from the inventor.
The Company has organized said Itonis Pharmaceuticals division and its Emesyl® and Emesyl® Product line
within its wholly-owned subsidiary, Itonis Holdings, Inc.
